Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
BoNidel, my point was about Accustem not Tils. And my post was just passing on some new official documentation which may have passed some by, and which is all we have in the absence of any other news.
But thanks for your interest.
This share got ramped to hell.
Predictions of £20 for Tils and £10 for Accustem.
What are both worth now?...
About 40p.
What a disgrace.
“ Our valuation assumes a 2027 regulatory approval and 2028 commer- cialization of foralumab for both pMS and CD in conjunction with part-Ners”
Who said Tils would not generate revenue until 2027??
Tils Aren’t expected to generate revenue until around 2027 IIRC. What’s your point?..
Only thing that matters to me at the moment is when is the NASDAQ uplist coming and what will the IPO price be ?
I think it said that last time around and it was always somewhat inevitable (and obvious I guess). One to stick in the bottom drawer and forget about.
"We do not expect to generate significant revenue from product sales for several years, if at all"
What a disgrace after all the ramping.
http://delivery.sec.report/JEIBQX?id=95272=dBkCBgwHBAMLS1ECCVMDVFBRAlZVAFtdBl9bDgQGBwhWXFcPDQFXVg8HBFdXUgNXWl5KBFYKBF9zAV1WVlVYXkUCU1gbUVlZRQYDUgFWBFBXUQdUBVZbAQRSRFFER0ULGEpWU1lbQFFLThsXVAceEQcWWRFHSih8eiRpYQ9aUU1BVg==&fl=XxFGRkYIGRtKUlZKQwFADBASGSdcBhdUVghMFgADBQADXAEHAAAbBgsaBVYDVgFbTQ==
Includes the statement, which I think we'd seen previously.
Management believes that the Company does not have sufficient cash and current assets to support its operations through at least 12 months from the issuance date of these condensed consolidated financial statements, and will require significant additional cash resources to continue its planned research and development activities.
I can't read half the table on the phone but I don't think there is any improvement not any material change. If someone can confirm that'd be handy